ATS Drug-Resistant Tuberculosis Treatment Guidelines Pocket Guide Cover

Drug-Resistant Tuberculosis GUIDELINES Pocket Guide

Treatment

Approved By

American Thoracic Society

Digital Subscription $4.99 Add to Cart
Print $9.95 Add to Cart
Free Sample

The digital subscription version of the Drug-Resistant Tuberculosis GUIDELINES Pocket Guide contains all the same great information found in the physical pocket guide, and can be accessed on mobile devices and online:

  • Price: $4.99 per year
    • Subscribe to additional guideline titles for discounted rates
  • Includes automatic updates during the term of your subscription
  • CPT® and ICD10 codes can be added to certain guidelines for an additional fee
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on the Guideline Central mobile app accessible without an internet connection
    • Access to additional guideline summaries, clinical calculators, and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

The Drug-Resistant Tuberculosis-Treatment Pocket Guide was developed in collaboration with the American Thoracic Society and is based on their latest Clinical Practice Guideline. This practical quick-reference tool contains graded recommendations for both adults and children, including potential adverse drug-drug Interactions.

  • Spiral-bound
  • 16 pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.25″ x 7.25″
  • Key Points
  • Summary of Good Practices
  • Treatment Recommendations
    • For the selection of an effective MDR-TB treatment regimen and duration of MDR-TB treatment
    • For the selection of oral drugs for MDR-TB treatment
    • For selected oral drugs previously included in regimens for the treatment of MDR-TB
    • For the selection of drugs administered through injection when needed to compose an effective treatment regimen for MDR-TB
    • For the use of the WHO-recommended standardized shorter-course 9–12 month regimen for MDR-TB
    • For the role of surgery in the treatment of MDR-TB
    • For the treatment of isoniazid-resistant TB
    • For the management of contacts to patients with MDR-TB
  • Tables
    • Summary of Recommendations on Drugs for Use in a Treatment Regimen for Patients with MDR-TB, Including Strength of Recommendation, Certainty in the Evidence and Relative Effects on Death and Treatment Success
    • Clinical Strategy to Build an Individualized Treatment Regimen for MDR-TB
    • Doses of Drugs for Treatment of Adults and Children with MDR-TB
    • Select Antiretroviral and Non–rifamycin-based Anti-tuberculosis Drug Overlapping Toxicities and Potential Adverse Drug-drug Interactions

The roots of the American Thoracic Society reach back to 1905, when a small group of physicians decided that the best way to improve care for tuberculosis patients was to share their experiences and discoveries. Today, the ATS has grown into an international society with more than 15,000 members. In this introductory section, you will find information about the people and programs that make the ATS the world's leading medical association dedicated to advancing our clinical and scientific understanding of pulmonary diseases, critical illnesses and sleep-related breathing disorders.

  • Guideline Pricing

  • Single Title
    $4.99 / year
  • Any 5 Titles
    $23.99 / year
  • Any 10 Titles
    $41.99 / year
  • Any 35 Titles
    $74.99 / year
  • All Available Titles
    $169.99 / year

To get started, log in or create your free account Create Account